ABSTRACT
In considering key events of genomic disorders in the development and progression of cancer, the correlation between genomic instability and carcinogenesis is currently under investigation. In this work, we propose an inductive logic programming approach to the problem of modeling evolution patterns for breast cancer. Using this approach, it is possible to extract fingerprints of stages of the disease that can be used in order to develop and deliver the most adequate therapies to patients. Furthermore, such a model can help physicians and biologists in the elucidation of molecular dynamics underlying the aberrations-waterfall model behind carcinogenesis. By showing results obtained on a real-world dataset, we try to give some hints about further approach to the knowledge-driven validations of such hypotheses.
Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Algorithms , Breast Neoplasms , Genetics , Comparative Genomic Hybridization , Computational Biology , DNA, Neoplasm , Genetics , Databases, Genetic , Logistic Models , Models, Genetic , Oligonucleotide Array Sequence AnalysisABSTRACT
<p><b>OBJECTIVE</b>To assess the optimal regimen and its mechanism of ZD1839 in combination with SN38, the active metabolite of irinotecan (CPT-11), in the colon cancer cell lines HT-29 and LoVo.</p><p><b>METHODS</b>Chou and Talalay method was used to analyze the combination effects of sequencing of ZD1839 and SN38. Western blotting and immunoprecipitation were used to determine the effects of ZD1839 and/or SN38 on their targeted enzymes and downstream markers. Apoptosis was assayed by analyzing histone-associated DNA fragment.</p><p><b>RESULTS</b>Sequential SN38 followed by ZD1839 produced a synergistic effect. In contrast, SN38 following ZD1839 exhibited an antagonist effect. SN38 markedly inhibited topoisomerase I (Topo-I) activity. ZD1839 did not alter epidermal growth factor receptor (EGFR) expression, but resulted in a complete inhibition of EGFR phosphorylation. Sequential ZD1839 followed by SN38 did not show any enhanced inhibition effect on Topo-I activity, phosphorylation of EGFR and one of its downstream markers MAPK. However, simultaneous SN38 plus ZD1839, and sequential SN38 followed by ZD1839 administrations showed modest inhibition effect on EGFR's another downstream marker AKT. The combination schedules also showed prominent influence on cell cycle distribution. ZD1839 maintained SN38-induced DNA damage and apoptosis.</p><p><b>CONCLUSION</b>Sequential SN38 followed by ZD1839 may be a favorable combination schedule.</p>
Subject(s)
Humans , Antineoplastic Agents , Pharmacology , Antineoplastic Agents, Phytogenic , Pharmacology , Apoptosis , Camptothecin , Pharmacology , Cell Cycle , Cell Line, Tumor , Cell Survival , Colonic Neoplasms , Metabolism , Pathology , DNA Topoisomerases, Type I , Metabolism , Drug Synergism , HT29 Cells , Inhibitory Concentration 50 , Mitogen-Activated Protein Kinase Kinases , Metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt , Metabolism , Quinazolines , Pharmacology , ErbB Receptors , Metabolism , Signal TransductionABSTRACT
<p><b>OBJECTIVE</b>To investigate the prognostic value of thymidylate synthase (TS), topoisomerase-1 (Topo-1), and proliferating index Ki-67 in advanced colorectal cancer patients on irinotecan (CPT-11) in combination with fluorouracil treatment (5-Fu).</p><p><b>METHODS</b>The biomarker expression of TS, Topo-1 and Ki-67 in 78 patients detected immunohistochemically were correlated with the clinical outcome.</p><p><b>RESULTS</b>The expressions of those biomarkers were not correlated with clinical therapeutic response, but with time to progression (TTP) and/or overall survival (OS). Patients with low expression of TS had significantly longer TTP (P < 0.05) and in OS (P < 0.05). The low expression of Ki-67 was also significantly predictive of longer survival (P < 0.05). As compared with any biomarker, the combination of any two biomarkers still possessed no predictive value to therapeutic response, but an enhanced predictive value to prognosis. The median time to progression in patients with low expression of TS, or Ki-67, or both were 9, 8 and 17 months, respectively; in patients with low expression of TS, or Topo-1, or both were 9, 9 and 13 months; in patients with low expression of Topo-1, or Ki-67, or both were 8, 9 and 11 months. TTP was significantly longer in patients with low expression of two biomarkers as compared with those with high expression (P = 0.031).</p><p><b>CONCLUSION</b>TS, Topo-1, and Ki-67 are not predictive for chemotherapy response to CPT-11 combined with 5-Fu, but valuable in predicting prognosis. The combination of any two biomarkers can provide more powerful prognostic information for advanced colorectal cancer patients.</p>